Loading...
The ideal treatment regimen for hepatitis C virus (HCV) infection would be interferon-free, simple (one pill a day would be best), and have high success rates in all genotypes and subpopulations (patients with cirrhosis, treatment-experienced patients) as well as minimal to no side effects. Recently, regimens combining sofosbuvir (a nucleotide polymerase inhibitor) and ledipasvir (an NS5A inhibitor) have successfully met most of those criteria in phase II studies of patients with HCV genotype 1 infection (NEJM JW Gastroenterol Nov 15 2013 and NEJM JW Gastroenterol Mar 28 2014). Now, phase III trial results are available.
In three industry-funded, randomized, open-label studies, investigators assessed the safety and efficacy of a single-pill,…